135 related articles for article (PubMed ID: 37042570)
21. Peritoneal Mesothelioma-An Update.
Malpica A
Adv Anat Pathol; 2023 Jul; 30(4):262-274. PubMed ID: 36729766
[TBL] [Abstract][Full Text] [Related]
22. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
23. Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.
Nizri E; Baratti D; Guaglio M; Sinukumar S; Cabras A; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jul; 44(7):1100-1104. PubMed ID: 29703622
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
Shamavonian R; Cheng E; Karpes JB; Barat S; Ahmadi N; Morris DL
Anticancer Res; 2022 Jun; 42(6):2939-2944. PubMed ID: 35641285
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
[TBL] [Abstract][Full Text] [Related]
26. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
[TBL] [Abstract][Full Text] [Related]
27. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
28. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
Hu ZI; Miettinen M; Quezado M; Lebensohn AP; Aldape K; Agra M; Wagner C; Mallory Y; Hassan R; Ghafoor A
J Thorac Oncol; 2022 Mar; 17(3):461-466. PubMed ID: 34628055
[TBL] [Abstract][Full Text] [Related]
29. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
30. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of diffuse malignant peritoneal mesothelioma.
Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
[TBL] [Abstract][Full Text] [Related]
33. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
[TBL] [Abstract][Full Text] [Related]
34. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
[TBL] [Abstract][Full Text] [Related]
35. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
37. New pathogenic germline variants identified in mesothelioma.
Belcaid L; Bertelsen B; Wadt K; Tuxen I; Spanggaard I; Højgaard M; Benn Sørensen J; Ravn J; Lassen U; Cilius Nielsen F; Rohrberg K; Westmose Yde C
Lung Cancer; 2023 May; 179():107172. PubMed ID: 36944283
[TBL] [Abstract][Full Text] [Related]
38. Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Rajha A; Piso P; Halmy L; Panczel I; Nedelcut DS; Herold Z; Szasz AM; Acs M
Anticancer Res; 2022 Jul; 42(7):3681-3692. PubMed ID: 35790287
[TBL] [Abstract][Full Text] [Related]
39. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
40. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
